Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
复制标题
DOI：
10.1158/2159-8290.cd-13-0314
复制
发表时间：
2013-12
期刊：
影响因子：
28.2
通讯作者：
Allen A
中科院分区：
文献类型：
--
作者：
Walter AO;Sjin RT;Haringsma HJ;Ohashi K;Sun J;Lee K;Dubrovskiy A;Labenski M;Zhu Z;Wang Z;Sheets M;St Martin T;Karp R;van Kalken D;Chaturvedi P;Niu D;Nacht M;Petter RC;Westlin W;Lin K;Jaw-Tsai S;Raponi M;Van Dyke T;Etter J;Weaver Z;Pao W;Singh J;Simmons AD;Harding TC;Allen A
Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond to first generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFR T790M mutation. CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M while exhibiting minimal activity towards the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition (EMT) and demonstrated increased sensitivity to AKT inhibitors. These results suggest CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.
